Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688513'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.27 Med: 12.01 Max: 27.65
Current: 10.28
During the past 13 years, Chengdu Easton Biopharmaceuticals Co's highest Return-on-Tangible-Equity was 27.65%. The lowest was 9.27%. And the median was 12.01%.
SHSE:688513's Return-on-Tangible-Equity is ranked better than 86.73% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs SHSE:688513: 10.28
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Equity Related Terms
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Equity Chart
SHSE:688513 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.71% mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Return-on-Tangible-Equity of 7.71% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 36% below median its historical median of 12.01. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity has ranged from 9.27 to 27.65. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #159 out of 1198 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity too high?
Chengdu Easton Biopharmaceuticals Co's current Return-on-Tangible-Equity of 7.71% is 36% below median its 10-year median of 12.01. Over the past 10 years, this metric has ranged from a low of 9.27 to a high of 27.65. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #159 out of 1198 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #159 out of 1198 companies for Return-on-Tangible-Equity. This places Chengdu Easton Biopharmaceuticals Co in the top 13% of its industry — outperforming the majority of peers. Historically, Chengdu Easton Biopharmaceuticals Co's own Return-on-Tangible-Equity has ranged from 9.27 to 27.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Return-on-Tangible-Equity is 7.71%, which is 36% below median its own 10-year median of 12.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥48.31, compared to a current price of ¥48.89 — trading 1.2% above its estimated fair value. The current Return-on-Tangible-Equity is 7.71%, which is 36% below median its 10-year median of 12.01. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Return-on-Tangible-Equity is 7.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥48.89 is trading 1.2% above its estimated GF Value™ of ¥48.31.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
Return-on-Tangible-Equity: 7.71% (36% below median its 10-year median of 12.01)
GF Value™: ¥48.31 vs. price of ¥48.89 (1.2% above fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
91GF Score
Get the complete analysis for SHSE:688513
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
